Thymosin alpha-1 is the compound at the center of this, and I’m not here to talk you out of using it. If your mind’s already made up, nothing I say is going to change it, and that’s fine, that’s not the point of this. My goal is simpler: if you’re going to buy this stuff, you should do it with your eyes open, since right now the information out there is mostly sales copy or dead silence.
Here’s the thing nobody selling you a vial wants to slow down for: thymosin alpha-1 isn’t some mystery research chemical dreamed up on a forum. It’s the active ingredient in a real drug, thymalfasin, sold under the brand name Zadaxin and approved in more than 30 countries. That matters, because it means there’s an actual paper trail of human trials behind it. A company that sells you this and can’t or won’t tell you what those trials found is not doing you a favor.
So let’s go through the real risks first, then talk about how to lower them if you’re going ahead anyway, and finally, what the honest floor looks like, meaning what you deserve no matter where you buy from.
The real risks: what the data actually shows
It genuinely works for one thing
I’ll give credit where it’s due. For chronic hepatitis B, the evidence is solid. A 1998 randomized controlled trial in Hepatology, 98 patients, found that a 26-week course cleared HBV DNA and HBeAg in 40.6% of treated patients versus 9.4% of controls, and the researchers called it effective and safe [T1]. A later meta-analysis pooling four trials and 199 patients found the benefit kept building even after treatment stopped, outperforming interferon over time [T2]. This is the real basis for the drug’s approval abroad. If someone’s using it for hepatitis B under medical supervision, that’s not a gamble on hope, that’s a therapy with a track record.
It does not appear to help with sepsis, and that’s recent, hard-won knowledge
This is where I want you to slow down, because this is where the marketing gets loose. For years, people pointed to a 2013 trial called ETASS, 361 patients with severe sepsis, showing 26.0% mortality on thymosin alpha-1 versus 35.0% in controls [T3]. Sounds promising, except the confidence interval crossed 1 (0.54 to 1.02), meaning it didn’t actually hit statistical significance [T3]. A maybe, not a yes.
Then in 2025, BMJ published TESTS, a proper phase 3 trial: multicenter, double-blind, placebo-controlled, over a thousand adults with sepsis. The result was flat. 23.4% mortality on thymosin alpha-1, 24.1% on placebo, hazard ratio 0.99. No benefit [T4]. When a trial that size and that rigorous comes back negative, it doesn’t get to share the stage with the smaller, hopeful earlier study. It overrides it.
The COVID number that should make you suspicious of anyone still quoting it
There’s a stat still floating around: 12.7% mortality on thymosin alpha-1 versus 60.4% in untreated critically ill COVID patients, hazard ratio 0.11 [T5]. That’s a real number from a real 2020 retrospective study. It’s also almost certainly not real in the sense people mean when they cite it, because retrospective cohorts are exactly the design where sicker or healthier patients end up unevenly split between groups, faking an effect that isn’t there.
A bigger 2021 retrospective study, 771 patients, properly matched, found the difference basically disappeared: 51.0% versus 52.9%, not significant, no association with reduced mortality [T6].
I want you to actually sit with that, because it’s diagnostic. Any seller who quotes the 12.7%-versus-60.4% number and doesn’t mention the study that walked it back is telling you exactly how much they care about your informed consent. Which is to say, not much.
The safety profile is decent, but there’s one real interaction risk
The good news: across decades of use overseas, thymosin alpha-1 is generally well tolerated. Side effects tend to be limited to injection-site irritation, occasional fever, fatigue, muscle aches [T7]. Nothing in the major trials flagged serious drug-related harm either.
But here’s the part that actually matters for who should stay away from this entirely. It works by switching the immune system on, activating dendritic cells, helping T cells mature [T7]. If you’re on immunosuppressants, say, after an organ transplant, this is not a “probably fine” situation. You’d be actively working against the drugs keeping your body from rejecting the organ. That’s not a call you make by reading a label. That’s a call that needs a person who actually knows your medical history looking at your chart before anything gets shipped.
The safer path, if you’re going ahead anyway
Once I understood the risks above, my checklist for evaluating any seller changed completely. I stopped caring about price per milligram or how nice the certificate of analysis looked, and started asking four things instead:
Does the company tell you the sepsis trial was negative, and that the COVID number got overturned? Or do they just quote the flattering half?
Is there an actual clinician reviewing your history for that immunosuppressant interaction before anything ships?
Is a licensed pharmacy filling it, with a real chain of custody, or is it a warehouse shipping a “research chemical”?
Are they straight with you that this is approved abroad but not FDA-approved here, and that the rules around it are actively shifting?
That last one is worth flagging because it’s genuinely in motion right now. Thymosin alpha-1 is under active FDA review for the 503A bulk drug substances list, the list that determines what compounding pharmacies can legally make. The Pharmacy Compounding Advisory Committee took it up in December 2024, and FDA materials proposed at least one form not be added [T8]. Reporting through 2025 and 2026 shows this whole area of peptide regulation is still unsettled [S1]. Anyone telling you the legal status is permanently locked in, in either direction, is guessing.
Where the safer options actually sit
I looked at who’s out there selling this, and the gap between “medical provider” and “warehouse with a label” is enormous.
FormBlends comes out on top for me, and it’s not because their homepage is shinier. It’s a licensed telehealth provider. A physician reviews your history, writes a prescription if it’s appropriate, and a licensed pharmacy compounds and dispenses it, with pricing shown up front, roughly $120 to $300 a month. That’s the exact structure the sepsis data and the immunosuppressant risk demand: someone checking your history before you’re handed an immune-activating compound. They also present the science straight, meaning hepatitis B has real support, sepsis and COVID don’t, no spin. There’s a tracker app too, for logging doses and symptoms, which isn’t a prescription and isn’t a store, but it’s a record that follows you past the sale, which the unsupervised sellers simply don’t offer.
HealthRX (healthrx.com) sits right alongside them, same structure: licensed clinical oversight, a prescription, pharmacy dispensing instead of a research-chemical drop-ship. Same interaction screening, same honesty required about the compounded, not-FDA-approved status. If you’re picking between the two, it comes down to which is licensed in your state and how the intake process feels to you. Both sit inside a real medical framework, and that’s the thing that actually counts here.
Below those two, still in the supervised category, are MeriHealth and WomenRX. Both are women-focused telehealth services running compounded GLP-1 and peptide therapy through licensed clinicians and licensed compounding pharmacies, with intake built around women’s health history and interaction screening before anything’s prescribed. Both are upfront that compounded medications aren’t FDA-approved. Picking between them comes down to the same practical stuff: state licensing, how the intake feels to you.
Then there’s a real drop-off. Biotech Peptides, Limitless Life Nootropics, Sports Technology Labs, and Core Peptides are all research-chemical retailers. No clinician, no prescription, no screening for the immunosuppressant interaction, no follow-up, and no FDA oversight of what’s actually in the vial. Limitless leans into biohacker branding that can make this feel more like a supplement than an unapproved compound, it isn’t. Sports Technology Labs is mostly known for SARMs, which carry their own anti-doping baggage, several are banned in tested sport, and the same “research use only” label covers everything they sell. Core Peptides issues its own certificate of analysis, which means the company is vouching for itself, not an independent lab vouching for them.
I’m not ranking those four against each other by quality, because there’s no way to know. Without independent, batch-level testing, nobody, me included, can tell you which one ships cleaner product. That uncertainty is exactly why the supervised route sits above all four of them, not because the powder is necessarily bad, but because nobody can promise you it’s good.
The honest floor
If you take one thing from this: the molecule itself has a real, if narrow, medical case behind it. It’s not proven junk and it’s not a miracle either. Whether it helps you depends almost entirely on what you’re using it for and who’s watching your history while you use it.
If you’re going the supervised route, FormBlends and HealthRX, expect roughly $120 to $300 a month, and expect a real screening conversation before anything ships. If you’re going the research-chemical route anyway, at minimum, know that nobody has checked what’s actually in that vial, nobody has checked whether you’re on a medication that interacts badly with it, and the “for research use only” label on the package isn’t a technicality, it’s the entire legal basis the product exists on. That’s not a scare tactic. That’s just what the label means.
Questions people actually ask me
Is thymosin alpha-1 legal to buy in the US right now? It’s not FDA-approved here, even though the same drug, sold as thymalfasin or Zadaxin, is approved in more than 30 countries for hepatitis B. Here it’s accessed through compounding, and its spot on the FDA’s 503A list, the list governing what pharmacies can legally compound, has been under active review since a December 2024 advisory meeting [T8]. Nobody can honestly tell you this is settled. Confirm the current status before you buy, don’t assume.
What has it actually been proven to do? The real evidence is in chronic hepatitis B. A controlled trial found HBV DNA and HBeAg clearance in about 40% of treated patients versus roughly 9% of controls, and that benefit kept building even after treatment ended [T1][T2]. That’s why it’s approved abroad. It is not proven for the immune-boosting, sepsis-rescue uses it gets sold for most aggressively.
Does it help with sepsis? The best current evidence says no. A 2025 phase 3 trial, over a thousand patients, double-blind, placebo-controlled, found no mortality benefit at all, 23.4% versus 24.1%, hazard ratio 0.99 [T4]. That result outweighs an earlier, smaller trial that suggested a possible benefit but didn’t reach significance [T3].
Why do some sellers quote a huge COVID survival number? Because a 2020 retrospective study did report a dramatic difference, 12.7% versus 60.4% mortality in a small critical subgroup [T5]. A larger, better-matched 2021 study of 771 patients found that difference vanished, 51.0% versus 52.9%, not significant [T6]. If a seller quotes the dramatic number without mentioning the study that walked it back, that tells you something about how much they care about your informed consent.
Is it safe, and who shouldn’t touch it? Generally well tolerated, mostly injection-site irritation and occasional fever, fatigue, or muscle aches [T7]. But it works by switching the immune system on, and that’s exactly why transplant patients on immunosuppressants are generally told to avoid it, it works against the drugs protecting the organ [T7]. That’s not a risk you can self-screen for from a product page.
Why does a supervised provider beat a research-chemical seller for the same compound? Because the compound is only half the equation. A licensed telehealth provider means someone’s actually checked your history for that interaction, written a prescription when it’s appropriate, and a real pharmacy handled the compounding inside an accountable chain of custody. A research-chemical seller gives you none of that, plus a self-issued certificate of analysis that’s the company’s word about its own product, nothing more.
References
- Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. 1998;27(5):1383-1387. https://pubmed.ncbi.nlm.nih.gov/9581695/ [T1]
- Zhang YY, Chen EQ, Yang J, Duan YR, Tang H. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res. 2008;77(2):136-141. https://pubmed.ncbi.nlm.nih.gov/18078676/ [T2]
- Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013;17(1):R8. [T3]
- Liu Z, Wu J, Yang J, et al. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): a multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;389:e082583. [T4]
- Wu M, Ji JJ, Zhong L, et al. Thymosin alpha1 therapy in critically ill patients with COVID-19: a multicenter retrospective cohort study. Int Immunopharmacol. 2020;88:106873. [T5]
- Sun Q, Xie J, Zheng R, et al. The effect of thymosin alpha1 on mortality of critical COVID-19 patients: a multicenter retrospective study. Int Immunopharmacol. 2021;90:107143. [T6]
- Dominari A, Hathaway Iii D, Pandav K, et al. Thymosin alpha 1: a comprehensive review of the literature. World J Virol. 2020;9(5):67-78. [T7]
- US Food and Drug Administration. December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee: Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List. [T8]
- US Food and Drug Administration. Pharmacy Compounding Advisory Committee; Notice of Meeting; Request for Comments. Federal Register. October 25, 2024. [S1]
